Literature DB >> 22808493

Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.

I A Kheyfets1, A A Spasov, M P Voronkova, J L Dugina, O I Epstein.   

Abstract

Antidiabetic activity of Subetta was revealed on the model of streptozotocin-induced diabetes mellitus in rats. Intragastric administration of this preparation in a dose of 5 ml/kg for 50 days reduced blood glucose levels, urine levels of glucose and ketone bodies, restored glucose tolerance in the oral glucose test, improved general condition and increased the survival rate of animals. The effectiveness of the drug was not inferior to that of rosiglitazone (8 mg/kg).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22808493     DOI： 10.1007/s10517-012-1641-8

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  4 in total

1.  Subetta increases phosphorylation of insulin receptor β-subunit alone and in the presence of insulin.

Authors:  E A Gorbunov; J Nicoll; E V Kachaeva; S A Tarasov; O I Epstein
Journal:  Nutr Diabetes       Date:  2015-07-06       Impact factor: 5.097

2.  Expression of Concern on "The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone".

Authors: 
Journal:  J Diabetes Res       Date:  2019-06-16       Impact factor: 4.011

3.  Subetta treatment increases adiponectin secretion by mature human adipocytes in vitro.

Authors:  Jim Nicoll; Evgeniy A Gorbunov; Sergey A Tarasov; Oleg I Epstein
Journal:  Int J Endocrinol       Date:  2013-04-18       Impact factor: 3.257

4.  The novel oral drug Subetta exerts an antidiabetic effect in the diabetic Goto-Kakizaki rat: comparison with rosiglitazone.

Authors:  Danielle Bailbé; Erwann Philippe; Evgeniy Gorbunov; Sergey Tarasov; Oleg Epstein; Bernard Portha
Journal:  J Diabetes Res       Date:  2013-05-08       Impact factor: 4.011
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.